Biotech Values

[biomaven0]

Lucentis vs. Avastin:

I suspect this was the reason for the more treatments in the Avastin arm:

“An alternative possibility is that patients in the ranibizumab group had a more robust and immediate response during the first 3 months than those in the bevacizumab group, (see Figure 2), and as OCT findings were the primary guide for re-treatment, the early and more dramatic change in foveal thickness in this treatment arm may have contributed to fewer injections over time.”

I haven't seen the latest foveal thickness results of the VEGF trap vs. Lucentis - in the earlier trials it looked to me that the VEGF trap was producing consistently better results.

Peter